Company news

GeneDx Holdings Corp. news in 2022

GeneDx Holdings Corp.'s news releases, calls and decks from 2022, newest first.

View company

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 29, 2022

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

December 4, 2022

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

November 13, 2022

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

November 3, 2022

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

October 30, 2022

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

October 26, 2022

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

October 25, 2022

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

October 4, 2022

Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

August 25, 2022

Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results

August 14, 2022

Sema4 Announces Changes to its Research & Development Leadership

August 14, 2022

Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

July 25, 2022

Sema4 Announces Chief Financial Officer Transition Plan

June 13, 2022

Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area

May 31, 2022

Sema4 to Participate at Two Investor Conferences in June 2022

May 25, 2022

Sema4 Reports First Quarter 2022 Financial Results and Business Highlights

May 11, 2022

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 3, 2022

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

May 1, 2022

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 25, 2022

Sema4 Achieves HITRUST CSF Certification

April 5, 2022

Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy

April 4, 2022

Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities

March 15, 2022

Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

March 13, 2022

Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022

March 7, 2022

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

February 21, 2022

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

February 21, 2022

Sema4 to Participate at Two Upcoming Investor Conferences in February

February 2, 2022

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities

January 31, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

January 17, 2022

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

January 9, 2022

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

January 2, 2022

Calls in 2022

Decks in 2022